Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

Inclusion Criteria: * Subjects must be able to understand and comply with the requirements of the study and communicate with the investigator * Diagnosis of chronic plaque psoriasis for at least 6 months before enrollment * Patients who were evaluated as candidates for systemic therapy, defined as having psoriasis intolerant or /and inadequately controlled by: topical treatment (including topical corticosteroid) and/or phototherapy and/or any previous systemic treatment for psoriasis or any previous treatment with biologic agents Exclusion Criteria: * Forms of psoriasis other than plaque psoriasis * Drug-induced psoriasis * Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA * Pregnant or nursing (lactating) women * Active ongoing inflammatory diseases other than psoriasis or psoriatic arthritis that might confound the evaluation of the benefit of secukinumab * Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions) * Pre-existing or recent-onset central or peripheral nervous system demyelinating disorders * Significant medical problems, including but not limited to the following: uncontrolled hypertension, congestive heart failure * Active systemic infections during the 2 weeks prior to enrollment * History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection * Past medical history record of, or current infection with, human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to enrollment * History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years * History or evidence of ongoing alcohol or drug abuse, within the last 6 months prior to enrollment * Plans for administration of live vaccines during the study period or in the 6 weeks prior to enrollment * Not willing to limit UV light exposure